◆ NeutralIRON
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
GlobeNewswire Inc.·
Disc Medicine, Inc. (NASDAQ: IRON) received a Complete Response Letter from the FDA on February 13, 2026, rejecting its bitopertin drug application due to uncertainties requiring additional evidence. The rejection caused the stock to plummet 22%. The Rosen Law Firm is now pursuing a class action lawsuit on behalf of shareholders who suffered losses, alleging the company issued materially misleading business information.
Read Full Article at GlobeNewswire Inc. →